BACKGROUND: The detection of monoclonal free light chains (FLCs) is an important diagnostic aid for a variety of monoclonal gammopathies and is especially important in light-chain diseases, such as light-chain myeloma, primary systemic amyloidosis, and light-chain-deposition disease. These diseases are more prevalent in the elderly, and assays to detect and quantify abnormal amounts of FLCs require reference intervals that include elderly donors. METHODS: We used an automated immunoassay for FLCs and sera from a population 21-90 years of age. We used the calculated reference and diagnostic intervals to compare FLC results with those obtained by immunofixation (IFE) to detect low concentrations of monoclonal kappa and lambda FLCs in the sera of patients with monoclonal gammopathies. RESULTS: Serum kappa and lambda FLCs increased with population age, with an apparent change for those >80 years. This trend was lost when the FLC concentration was normalized to cystatin C concentration. The ratio of kappa FLC to lambda FLC (FLC K/L) did not exhibit an age-dependent trend. The diagnostic interval for FLC K/L was 0.26-1.65. The 95% reference interval for kappa FLC was 3.3-19.4 mg/L, and that for lambda FLC was 5.7-26.3 mg/L. Detection and quantification of monoclonal FLCs by nephelometry were more sensitive than IFE in serum samples from patients with primary systemic amyloidosis and light-chain-deposition disease. CONCLUSIONS: Reference and diagnostic intervals for serum FLCs have been developed for use with a new, automated immunoassay that makes the detection and quantification of monoclonal FLCs easier and more sensitive than with current methods. The serum FLC assay complements IFE and allows quantification of FLCs in light-chain-disease patients who have no detectable serum or urine M-spike.
BACKGROUND: The detection of monoclonal free light chains (FLCs) is an important diagnostic aid for a variety of monoclonal gammopathies and is especially important in light-chain diseases, such as light-chain myeloma, primary systemic amyloidosis, and light-chain-deposition disease. These diseases are more prevalent in the elderly, and assays to detect and quantify abnormal amounts of FLCs require reference intervals that include elderly donors. METHODS: We used an automated immunoassay for FLCs and sera from a population 21-90 years of age. We used the calculated reference and diagnostic intervals to compare FLC results with those obtained by immunofixation (IFE) to detect low concentrations of monoclonal kappa and lambda FLCs in the sera of patients with monoclonal gammopathies. RESULTS: Serum kappa and lambda FLCs increased with population age, with an apparent change for those >80 years. This trend was lost when the FLC concentration was normalized to cystatin C concentration. The ratio of kappa FLC to lambda FLC (FLC K/L) did not exhibit an age-dependent trend. The diagnostic interval for FLC K/L was 0.26-1.65. The 95% reference interval for kappa FLC was 3.3-19.4 mg/L, and that for lambda FLC was 5.7-26.3 mg/L. Detection and quantification of monoclonal FLCs by nephelometry were more sensitive than IFE in serum samples from patients with primary systemic amyloidosis and light-chain-deposition disease. CONCLUSIONS: Reference and diagnostic intervals for serum FLCs have been developed for use with a new, automated immunoassay that makes the detection and quantification of monoclonal FLCs easier and more sensitive than with current methods. The serum FLC assay complements IFE and allows quantification of FLCs in light-chain-disease patients who have no detectable serum or urine M-spike.
Authors: Colin A Hutchison; Vecihi Batuman; Judith Behrens; Frank Bridoux; Christophe Sirac; Angela Dispenzieri; Guillermo A Herrera; Helen Lachmann; Paul W Sanders Journal: Nat Rev Nephrol Date: 2011-11-01 Impact factor: 28.314
Authors: Shaji Kumar; Angela Dispenzieri; Jerry A Katzmann; Dirk R Larson; Colin L Colby; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Nelson Leung; Steve R Zeldenrust; Marina Ramirez-Alvarado; Raynell J Clark; Robert A Kyle; S Vincent Rajkumar; Morie A Gertz Journal: Blood Date: 2010-08-26 Impact factor: 22.113
Authors: Carrie A Thompson; Matthew J Maurer; James R Cerhan; Jerry A Katzmann; Stephen M Ansell; Thomas M Habermann; William R Macon; George J Weiner; Brian K Link; Thomas E Witzig Journal: Am J Hematol Date: 2011-10-17 Impact factor: 10.047
Authors: Angela Dispenzieri; Martha Q Lacy; Jerry A Katzmann; S Vincent Rajkumar; Roshini S Abraham; Suzanne R Hayman; Shaji K Kumar; Raynell Clark; Robert A Kyle; Mark R Litzow; David J Inwards; Stephen M Ansell; Ivana M Micallef; Luis F Porrata; Michelle A Elliott; Patrick B Johnston; Philip R Greipp; Thomas E Witzig; Steven R Zeldenrust; Stephen J Russell; Dennis Gastineau; Morie A Gertz Journal: Blood Date: 2006-01-05 Impact factor: 22.113
Authors: Sophie Desplat-Jégo; Lionel Feuillet; Jean Pelletier; Dominique Bernard; André Ali Chérif; José Boucraut Journal: J Clin Immunol Date: 2005-07 Impact factor: 8.317
Authors: David Dingli; Robert A Kyle; S Vincent Rajkumar; Grzegorz S Nowakowski; Dirk R Larson; John P Bida; Morie A Gertz; Terry M Therneau; L Joseph Melton; Angela Dispenzieri; Jerry A Katzmann Journal: Blood Date: 2006-06-01 Impact factor: 22.113
Authors: Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar Journal: Blood Date: 2009-01-29 Impact factor: 22.113
Authors: Sandra Davern; Lian X Tang; Teresa K Williams; Sallie D Macy; Jonathan S Wall; Deborah T Weiss; Alan Solomon Journal: Am J Clin Pathol Date: 2008-11 Impact factor: 2.493